Literature DB >> 21546502

Predictors of osteoclast activity in patients with sickle cell disease.

Mehdi Nouraie1, Kevin Cheng, Xiaomei Niu, Evadne Moore-King, Margaret F Fadojutimi-Akinsi, Caterina P Minniti, Craig Sable, Sohail Rana, Niti Dham, Andrew Campbell, Gregory Ensing, Gregory J Kato, Mark T Gladwin, Oswaldo L Castro, Victor R Gordeuk.   

Abstract

BACKGROUND: Bone changes are common in sickle cell disease, but the pathogenesis is not fully understood. Tartrate-resistant acid phosphatase (TRACP) type 5b is produced by bone-resorbing osteoclasts. In other forms of hemolytic anemia, increased iron stores are associated with osteoporosis. We hypothesized that transfusional iron overload would be associated with increased osteoclast activity in patients with sickle cell disease. DESIGN AND METHODS: We examined tartrate-resistant acid phosphatase 5b concentrations in patients with sickle cell disease and normal controls of similar age and sex distribution at steady state. Serum tartrate-resistant acid phosphatase 5b concentration was measured using an immunocapture enzyme assay and plasma concentrations of other cytokines were assayed using the Bio-Plex suspension array system. Tricuspid regurgitation velocity, an indirect measure of systolic pulmonary artery pressure, was determined by echocardiography.
RESULTS: Tartrate-resistant acid phosphatase 5b concentrations were higher in 58 adults with sickle cell disease than in 22 controls (medians of 4.4 versus 2.4 U/L, respectively; P=0.0001). Among the patients with sickle cell disease, tartrate-resistant acid phosphatase 5b independently correlated with blood urea nitrogen (standardized beta=0.40, P=0.003), interleukin-8 (standardized beta=0.30, P=0.020), and chemokine C-C motif ligand 5 (standardized beta=-0.28, P=0.031) concentrations, but not with serum ferritin concentration. Frequent blood transfusions (>10 units in life time) were not associated with higher tartrate-resistant acid phosphatase 5b levels in multivariate analysis. There were strong correlations among tartrate-resistant acid phosphatase 5b, alkaline phosphatase and tricuspid regurgitation velocity (r>0.35, P<0.001).
CONCLUSIONS: Patients with sickle cell disease have increased osteoclast activity as reflected by serum tartrate-resistant acid phosphatase 5b concentrations. Our results may support a potential role of inflammation rather than increased iron stores in stimulating osteoclast activity in sickle cell disease. The positive relationships among tartrate-resistant acid phosphatase 5b, alkaline phosphatase and tricuspid regurgitation velocity raise the possibility of a common pathway in the pulmonary and bone complications of sickle cell disease.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21546502      PMCID: PMC3148901          DOI: 10.3324/haematol.2011.042499

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  51 in total

Review 1.  Bone disease and skeletal complications in patients with β thalassemia major.

Authors:  Rachid Haidar; Khaled M Musallam; Ali T Taher
Journal:  Bone       Date:  2010-10-28       Impact factor: 4.398

Review 2.  Interleukin-6 in bone metastasis and cancer progression.

Authors:  Tasnim Ara; Yves A Declerck
Journal:  Eur J Cancer       Date:  2010-03-23       Impact factor: 9.162

3.  Plasma inflammatory mediators associated with bone metabolism in COPD.

Authors:  Jessica M Bon; Yingze Zhang; Steven R Duncan; Joseph M Pilewski; Diana Zaldonis; Adriana Zeevi; Kenneth R McCurry; Susan L Greenspan; Frank C Sciurba
Journal:  COPD       Date:  2010-06       Impact factor: 2.409

4.  Does high serum iron level induce low bone mass in sickle cell anemia ?

Authors:  Mir Sadat-Ali; Osama Sultan; Haifa Al-Turki; Abdulmohsen Alelq
Journal:  Biometals       Date:  2010-11-26       Impact factor: 2.949

5.  High levels of placenta growth factor in sickle cell disease promote pulmonary hypertension.

Authors:  Nambirajan Sundaram; Anitaben Tailor; Laurel Mendelsohn; Janaka Wansapura; Xunde Wang; Tomoyasu Higashimoto; Michael W Pauciulo; William Gottliebson; Vijay K Kalra; William C Nichols; Gregory J Kato; Punam Malik
Journal:  Blood       Date:  2010-03-24       Impact factor: 22.113

Review 6.  The role of interleukin-6 in rheumatoid arthritis-associated osteoporosis.

Authors:  C J Edwards; E Williams
Journal:  Osteoporos Int       Date:  2010-03-13       Impact factor: 4.507

7.  Bone loss caused by iron overload in a murine model: importance of oxidative stress.

Authors:  Jaime Tsay; Zheiwei Yang; F Patrick Ross; Susanna Cunningham-Rundles; Hong Lin; Rhima Coleman; Philipp Mayer-Kuckuk; Stephen B Doty; Robert W Grady; Patricia J Giardina; Adele L Boskey; Maria G Vogiatzi
Journal:  Blood       Date:  2010-06-16       Impact factor: 22.113

8.  Ferritin ferroxidase activity: a potent inhibitor of osteogenesis.

Authors:  Abolfazl Zarjou; Viktória Jeney; Paolo Arosio; Maura Poli; Erzsébet Zavaczki; György Balla; József Balla
Journal:  J Bone Miner Res       Date:  2010-01       Impact factor: 6.741

9.  Biology and clinical significance of tartrate-resistant acid phosphatases: new perspectives on an old enzyme.

Authors:  Anthony J Janckila; Lung T Yam
Journal:  Calcif Tissue Int       Date:  2009-11-14       Impact factor: 4.333

10.  Bone metabolism after cinacalcet administration in patients with secondary hyperparathyroidism.

Authors:  Shozo Yano; Keiko Suzuki; Masaaki Sumi; Akihide Tokumoto; Kazushi Shigeno; Yasutoshi Himeno; Toshitsugu Sugimoto
Journal:  J Bone Miner Metab       Date:  2009-06-23       Impact factor: 2.626

View more
  6 in total

1.  Microarchitectural and mechanical characterization of the sickle bone.

Authors:  Mykel Green; Idowu Akinsami; Angela Lin; Shereka Banton; Samit Ghosh; Binbin Chen; Manu Platt; Ifeyinwa Osunkwo; Solomon Ofori-Acquah; Robert Guldberg; Gilda Barabino
Journal:  J Mech Behav Biomed Mater       Date:  2015-04-24

Review 2.  Targeting the Hematopoietic Stem Cell Niche in β-Thalassemia and Sickle Cell Disease.

Authors:  Annamaria Aprile; Silvia Sighinolfi; Laura Raggi; Giuliana Ferrari
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-11

3.  Nrf2 deficiency in mice attenuates erythropoietic stress-related macrophage hypercellularity.

Authors:  Oluwabukola T Gbotosho; Maria G Kapetanaki; Mark Ross; Samit Ghosh; Frances Weidert; Grant C Bullock; Simon Watkins; Solomon F Ofori-Acquah; Gregory J Kato
Journal:  Exp Hematol       Date:  2020-03-06       Impact factor: 3.084

4.  Impairment of bone health in pediatric patients with hemolytic anemia.

Authors:  Michael M Schündeln; Sarah C Goretzki; Pia K Hauffa; Regina Wieland; Jens Bauer; Lena Baeder; Angelika Eggert; Berthold P Hauffa; Corinna Grasemann
Journal:  PLoS One       Date:  2014-10-09       Impact factor: 3.240

Review 5.  Mechanisms of Bone Impairment in Sickle Bone Disease.

Authors:  Paola Giordano; Flavia Urbano; Giuseppe Lassandro; Maria Felicia Faienza
Journal:  Int J Environ Res Public Health       Date:  2021-02-13       Impact factor: 3.390

6.  Development of Algorithm for Clinical Management of Sickle Cell Bone Disease: Evidence for a Role of Vertebral Fractures in Patient Follow-up.

Authors:  Lucia De Franceschi; Daniele Gabbiani; Andrea Giusti; Gianluca Forni; Filippo Stefanoni; Valeria Maria Pinto; Giulia Sartori; Manuela Balocco; Chiara Dal Zotto; Maria Teresa Valenti; Luca Dalle Carbonare
Journal:  J Clin Med       Date:  2020-05-25       Impact factor: 4.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.